In detail, the frequency of non‐functional TP53 mutations increased from 2.8% in BC cases with optimal EPR (group I) to 18.2% in BCs with severely impaired EPR (group IV, p < 0.0001, Figure 4C). The gene discussed is TP53; the disease is breast cancer.